In thyroidectomized patients with thyroid cancer, a serum thyrotropin of 30 μu/ml after thyroxine withdrawal is not always adequate for detecting an elevated stimulated serum thyroglobulin

Thyroid

Volumn 23, Issue 2, 2013, Pages 185-193

  Valle, Laticia A ^a,b   Gorodeski Baskin, Revital L ^a,b   Porter, Kyle ^a,b   Sipos, Jennifer A ^a,b   Khawaja, Raheela ^a,b   Ringel, Matthew D ^a,b   Kloos, Richard T ^a,b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c Veracyte Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THYROGLOBULIN; THYROID HORMONE; THYROTROPIN; THYROXINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE; HORMONAL REGULATION; HUMAN; HYPOTHYROIDISM; LONGITUDINAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; REFERENCE VALUE; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION;

ADULT; AGED; HUMANS; HYPOTHYROIDISM; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; SUBSTANCE WITHDRAWAL SYNDROME; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN; THYROXINE;

EID: 84873664744     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2012.0327     Document Type: Article

References (40)

1. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
2. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, Lippi F, Taddei D, Grasso L, Pinchera A 2003 Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 88:3668-3673.
3. Mazzaferri EL, Kloos RT 2002 Is diagnostic iodine-131 scanning with recombinant human TSH useful in the followup of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 87:1490-1498.
4. Wartofsky L 2002 Management of low-risk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin. Thyroid 12:583-590.
5. Kloos RT, Mazzaferri EL 2005 A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 90:5047-5057.
6. Kloos RT 2010 Thyroid cancer recurrence in patients clinically free of disease with undetectable or very low serum thyroglobulin values. J Clin Endocrinol Metab 95:5241-5248.
7. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR, 3rd, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC 1999 A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84:3877-3885.
8. Brassard M, Borget I, Edet-Sanson A, Giraudet AL, Mundler O, Toubeau M, Bonichon F, Borson-Chazot F, Leenhardt L, Schvartz C, Dejax C, Brenot-Rossi I, Toubert ME, Torlontano M, Benhamou E, Schlumberger M 2011 Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab 96:1352-1359.
9. Schlumberger M, Hitzel A, Toubert ME, Corone C, Troalen F, SchlageterMH, Claustrat F, Koscielny S, Taieb D, ToubeauM, Bonichon F, Borson-Chazot F, Leenhardt L, Schvartz C, Dejax C, Brenot-Rossi I, Torlontano M, Tenenbaum F, Bardet S, Bussiere F, Girard JJ, Morel O, Schneegans O, Schlienger JL, Prost A, So D, Archambeaud F, Ricard M, Benhamou E 2007 Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab 92:2487-2495.
10. Edmonds CJ, Hayes S, Kermode JC, Thompson BD 1977 Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. Br J Radiol 50:799-807.
11. Tamai H, Suemastu H, Kurokawa N, Esaki M, Ikemi T, Matsuzuka F, Kuma K, Nagataki S 1979 Alterations in circulating thyroid hormones and thyrotropin after complete thyroidectomy. J Clin Endocrinol Metab 48:54-58.
12. Hilts SV, Hellman D, Anderson J, Woolfenden J, Van Antwerp J, Patton D 1979 Serial TSH determination after T3 withdrawal or thyroidectomy in the therapy of thyroid carcinoma. J Nucl Med 20:928-932.
13. Hershman JM, Edwards CL 1972 Serum thyrotropin (TSH) levels after thyroid ablation compared with TSH levels after exogenous bovine TSH: implications for 131-I treatment of thyroid carcinoma. J Clin Endocrinol Metab 34:814-818.
14. Goldman JM, Line BR, Aamodt RL, Robbins J 1980 Influence of triiodothyronine withdrawal time on 131I uptake postthyroidectomy for thyroid cancer. J Clin Endocrinol Metab 50:734-739.
15. Serhal DI, Nasrallah MP, Arafah BM 2004 Rapid rise in serum thyrotropin concentrations after thyroidectomy or withdrawal of suppressive thyroxine therapy in preparation for radioactive iodine administration to patients with differentiated thyroid cancer. J Clin Endocrinol Metab 89: 3285-3289.
16. Kuijt WJ, Huang SA 2005 Children with differentiated thyroid cancer achieve adequate hyperthyrotropinemia within 14 days of levothyroxine withdrawal. J Clin Endocrinol Metab 90:6123-6125.
17. Grigsby PW, Siegel BA, Bekker S, Clutter WE, Moley JF 2004 Preparation of patients with thyroid cancer for 131I scintigraphy or therapy by 1-3 weeks of thyroxine discontinuation. J Nucl Med 45:567-570.
18. Sanchez R, Espinosa-de-los-Monteros AL, Mendoza V, Brea E, Hernandez I, Sosa E, Mercado M 2002 Adequate thyroidstimulating hormone levels after levothyroxine discontinuation in the follow-up of patients with well-differentiated thyroid carcinoma. Arch Med Res 33:478-481.
19. Liel Y 2002 Preparation for radioactive iodine administration in differentiated thyroid cancer patients. Clin Endocrinol (Oxf) 57:523-527.
20. Tahboub RM, Nyalakonda K, Arafah BM 2009 Change in serum TSH and thyroglobulin levels in patients with differentiated thyroid cancer after short-term thyroid hormone withdrawal: an effective approach in monitoring patients and disease surveillance. The Endocrine Society, ENDO 09 91st Annual Meeting. Abstract no. OR12-05.
21. Taieb D, Sebag F, Cherenko M, Baumstarck-Barrau K, Fortanier C, Farman-Ara B, De Micco C, Vaillant J, Thomas S, Conte-Devolx B, Loundou A, Auquier P, Henry JF, Mundler O 2009 Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study. Clin Endocrinol (Oxf) 71: 115-123.
22. Taieb D, Baumstarck-Barrau K, Sebag F, Fortanier C, De Micco C, Loundou A, Auquier P, Palazzo FF, Henry JF, Mundler O 2011 Heath-related quality of life in thyroid cancer patients following radioiodine ablation. Health Qual Life Outcomes 9:33.
23. Billewicz WZ, Chapman RS, Crooks J, Day ME, Gossage J, Wayne E, Young JA 1969 Statistical methods applied to the diagnosis of hypothyroidism. Q J Med 38:255-266.
24. Shacham S 1983 A shortened version of the profile of mood states. J Pers Assess 47:305-306.
25. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, SchuffKG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Weintraub BD, Ridgway EC, Ladenson PW 2006 A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. The Journal of clinical endocrinology and metabolism 91:878-884.
26. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C 2006 Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91:926-932.
27. Luster M, Felbinger R, Dietlein M, Reiners C 2005 Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid 15:1147-1155.
28. Lee J, Yun MJ, Nam KH, Chung WY, Soh EY, Park CS 2010 Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid 20:173-179.
29. Dueren C, Dietlein M, Luster M, Plenzig F, Steinke R, Grimm J, Groth P, Eichhorn W, Reiners C 2010 The use of thyrogen in the treatment of differentiated thyroid carcinoma: an intraindividual comparison of clinical effects and implications of daily life. Exp Clin Endocrinol Diabetes 118: 513-519.
30. Dow KH, Ferrell BR, Anello C 1997 Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 7:613-619.
31. Davids T, Witterick IJ, Eski S, Walfish PG, Freeman JL 2006 Three-week thyroxine withdrawal: a thyroid-specific quality of life study. Laryngoscope 116:250-253.
32. Chow SM, Au KH, Choy TS, Lee SH, Yeung NY, Leung A, Leung A, Leung HL, Shek CC, Law SC 2006 Health-related quality-of-life study in patients with carcinoma of the thyroid after thyroxine withdrawal for whole body scanning. Laryngoscope 116:2060-2066.
33. Sobin L, Gospodaraowicz M, Wittekind C 2009 TNM Classification of Malignant Tumours. Seventh edition. Wiley-Blackwell, Hoboken, NJ, pp 58-62.
34. Spencer C, Fatemi S, Singer P, Nicoloff J, Lopresti J 2010 Serum basal thyroglobulin measured by a secondgeneration assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer. Thyroid 20: 587-595.
35. Pacini F, Molinaro E, Lippi F, Castagna MG, Agate L, Ceccarelli C, Taddei D, Elisei R, Capezzone M, Pinchera A 2001 Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab 86:5686-5690.
36. Leboeuf R, Perron P, Carpentier AC, Verreault J, Langlois MF 2007 L-T3 preparation for whole-body scintigraphy: a randomized-controlled trial. Clin Endocrinol (Oxf) 67:839-844.
37. Husson O, Haak HR, Oranje WA, Mols F, Reemst PH, van de Poll-Franse LV 2011 Health-related quality of life among thyroid cancer survivors: a systematic review. Clin Endocrinol (Oxf) 75:544-554.
38. Helfand M 2004 Screening for subclinical thyroid dysfunction in nonpregnant adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 140:128-141.
39. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC 2000 The Colorado thyroid disease prevalence study. Arch Intern Med 160:526-534.
40. Lindeman RD, Schade DS, LaRue A, Romero LJ, Liang HC, Baumgartner RN, Koehler KM, Garry PJ 1999 Subclinical hypothyroidism in a biethnic, urban community. J Am Geriatr Soc 47:703-709.